import { Drug } from '@/types';

export const antipsychoticsData: Drug[] = [
  {
    id: 'haloperidol',
    name: 'Haloperidol',
    class: 'First-Generation Antipsychotic (FGA) / Typical',
    mechanism: 'High-potency D2 dopamine receptor antagonist. Strong dopamine blockade in mesolimbic pathway (antipsychotic effect) and nigrostriatal pathway (EPS).',
    indications: [
      'Schizophrenia',
      'Acute agitation',
      'Tourette syndrome',
      'Delirium',
      'Psychosis',
    ],
    contraindications: [
      'Parkinson disease',
      'CNS depression/coma',
      'QT prolongation',
    ],
    sideEffects: [
      'Extrapyramidal symptoms (EPS): dystonia, parkinsonism, akathisia',
      'Tardive dyskinesia (chronic use)',
      'Neuroleptic malignant syndrome (rare)',
      'QT prolongation',
      'Sedation',
      'Hyperprolactinemia',
    ],
    interactions: [
      'QT-prolonging drugs',
      'CYP3A4 and CYP2D6 substrate',
      'Anticholinergics may worsen psychosis',
    ],
    monitoring: [
      'EPS and movement disorders',
      'Abnormal Involuntary Movement Scale (AIMS) for tardive dyskinesia',
      'ECG (QTc)',
      'Prolactin if symptomatic',
    ],
    dosing: {
      starting: '0.5-5 mg BID-TID (oral); 2-5 mg IM PRN (agitation)',
      therapeutic: '5-20 mg daily',
      maximum: 'Variable; typically â‰¤100 mg daily',
    },
    switchingNotes: [
      'Can directly switch to SGAs',
      'Taper if chronic use to avoid withdrawal dyskinesia',
    ],
    warnings: [
      'Black box (in dementia-related psychosis): Increased mortality',
      'High risk of EPS',
      'Tardive dyskinesia risk increases with duration',
      'QT prolongation risk, especially IV',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Excreted in milk; weigh risks.',
      geriatric: 'Beers Criteria: avoid in dementia; high fall/stroke risk.',
      renal: 'Caution.',
      hepatic: 'Caution; lower doses.',
    },
  },
  {
    id: 'risperidone',
    name: 'Risperidone',
    class: 'Second-Generation Antipsychotic (SGA) / Atypical',
    mechanism: 'D2 and 5-HT2A antagonist. At higher doses, acts more like FGA with increased EPS risk.',
    indications: [
      'Schizophrenia',
      'Bipolar mania',
      'Irritability in autism (pediatric)',
    ],
    contraindications: [
      'Hypersensitivity',
    ],
    sideEffects: [
      'EPS (dose-dependent, especially >6 mg)',
      'Hyperprolactinemia (highest among SGAs)',
      'Weight gain',
      'Orthostatic hypotension',
      'Sedation',
      'Sexual dysfunction',
      'Metabolic effects',
    ],
    interactions: [
      'CYP2D6 substrate',
      'QT prolongation (less than FGAs)',
    ],
    monitoring: [
      'Prolactin if symptomatic (galactorrhea, amenorrhea)',
      'Weight, glucose, lipids (metabolic panel)',
      'Blood pressure',
      'EPS',
    ],
    dosing: {
      starting: '1-2 mg daily',
      therapeutic: '2-6 mg daily',
      maximum: '16 mg daily',
    },
    switchingNotes: [
      'Can switch to other SGAs',
      'Taper if high dose to avoid withdrawal',
    ],
    warnings: [
      'Black box (dementia-related psychosis): Increased mortality',
      'Highest hyperprolactinemia risk among SGAs',
      'EPS risk increases at higher doses',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Excreted in milk; caution.',
      geriatric: 'Increased stroke risk; avoid in dementia.',
      renal: 'Reduce dose in renal impairment.',
      hepatic: 'Reduce dose in hepatic impairment.',
    },
  },
  {
    id: 'olanzapine',
    name: 'Olanzapine',
    class: 'Second-Generation Antipsychotic (SGA) / Atypical',
    mechanism: 'D2, 5-HT2A, H1, and muscarinic antagonist. Strong metabolic effects.',
    indications: [
      'Schizophrenia',
      'Bipolar mania',
      'Bipolar maintenance',
      'Agitation (IM)',
      'Treatment-resistant depression (with fluoxetine)',
    ],
    contraindications: [
      'Hypersensitivity',
    ],
    sideEffects: [
      'Significant weight gain (highest risk)',
      'Metabolic syndrome (diabetes, dyslipidemia)',
      'Sedation',
      'Anticholinergic effects',
      'Orthostatic hypotension',
      'Low EPS risk',
    ],
    interactions: [
      'CYP1A2 substrate (smoking decreases levels)',
      'Additive anticholinergic effects',
    ],
    monitoring: [
      'Weight (baseline and regularly)',
      'Fasting glucose and HbA1c',
      'Lipid panel',
      'Blood pressure',
    ],
    dosing: {
      starting: '5-10 mg daily',
      therapeutic: '10-20 mg daily',
      maximum: '30 mg daily',
    },
    switchingNotes: [
      'Taper if switching due to metabolic effects',
      'Direct switch to other SGAs possible',
    ],
    warnings: [
      'Black box (dementia-related psychosis): Increased mortality',
      'Highest weight gain and metabolic risk among SGAs',
      'Monitor for diabetes',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Excreted in milk; caution.',
      geriatric: 'Avoid in dementia; metabolic and sedation risks.',
      renal: 'No adjustment needed.',
      hepatic: 'Consider lower starting dose.',
    },
  },
  {
    id: 'quetiapine',
    name: 'Quetiapine',
    class: 'Second-Generation Antipsychotic (SGA) / Atypical',
    mechanism: 'D2 and 5-HT2A antagonist. Low D2 affinity; also has metabolite (norquetiapine) with NET inhibition.',
    indications: [
      'Schizophrenia',
      'Bipolar mania and depression',
      'Bipolar maintenance',
      'Adjunct in major depression (XR formulation)',
    ],
    contraindications: [
      'Hypersensitivity',
    ],
    sideEffects: [
      'Sedation (especially at lower doses)',
      'Weight gain',
      'Metabolic effects',
      'Orthostatic hypotension',
      'Tachycardia',
      'Low EPS risk',
      'Cataracts (theoretical, from animal studies)',
    ],
    interactions: [
      'CYP3A4 substrate',
      'Antihypertensives: additive hypotension',
    ],
    monitoring: [
      'Weight, glucose, lipids',
      'Blood pressure',
      'Eye exam at baseline (cataracts)',
    ],
    dosing: {
      starting: '25-50 mg BID (IR); 50-300 mg QHS (XR)',
      therapeutic: '300-800 mg daily',
      maximum: '800 mg daily',
    },
    switchingNotes: [
      'Can switch to other SGAs',
      'XR formulation approved for depression adjunct',
    ],
    warnings: [
      'Black box (dementia-related psychosis): Increased mortality',
      'Sedation and orthostatic hypotension, especially early',
      'Metabolic effects',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Excreted in milk; caution.',
      geriatric: 'Avoid in dementia; high sedation/fall risk.',
      renal: 'No adjustment.',
      hepatic: 'Start with lower dose.',
    },
  },
  {
    id: 'aripiprazole',
    name: 'Aripiprazole',
    class: 'Second-Generation Antipsychotic (SGA) / Atypical',
    mechanism: 'Partial D2 agonist (dopamine system stabilizer) and 5-HT2A antagonist. Lower metabolic and sedation risk.',
    indications: [
      'Schizophrenia',
      'Bipolar mania',
      'Bipolar maintenance',
      'Adjunct in major depression',
      'Irritability in autism (pediatric)',
      'Tourette syndrome',
    ],
    contraindications: [
      'Hypersensitivity',
    ],
    sideEffects: [
      'Akathisia (very common)',
      'Restlessness/agitation',
      'Insomnia',
      'Nausea',
      'Low weight gain and metabolic risk',
      'Low sedation',
      'EPS (mild)',
    ],
    interactions: [
      'CYP3A4 and CYP2D6 substrate',
      'Dose adjustment needed with strong CYP inhibitors/inducers',
    ],
    monitoring: [
      'Akathisia',
      'Weight, glucose, lipids (lower risk but still monitor)',
      'Mood and behavior',
    ],
    dosing: {
      starting: '10-15 mg daily',
      therapeutic: '15-30 mg daily',
      maximum: '30 mg daily',
    },
    switchingNotes: [
      'Often chosen when switching from high metabolic risk SGA',
      'Akathisia may be limiting',
    ],
    warnings: [
      'Black box (dementia-related psychosis): Increased mortality; (antidepressant adjunct): suicidality',
      'Very high akathisia risk',
      'Impulse control disorders reported (gambling, hypersexuality)',
    ],
    specialPopulations: {
      pregnancy: 'Category C.',
      lactation: 'Excreted in milk; caution.',
      geriatric: 'Avoid in dementia.',
      renal: 'No adjustment.',
      hepatic: 'No adjustment.',
    },
  },
  {
    id: 'clozapine',
    name: 'Clozapine',
    class: 'Second-Generation Antipsychotic (SGA) / Atypical',
    mechanism: 'D2, 5-HT2A, H1, muscarinic antagonist. "Gold standard" for treatment-resistant schizophrenia. Only antipsychotic shown to reduce suicide risk.',
    indications: [
      'Treatment-resistant schizophrenia',
      'Reduction of suicide risk in schizophrenia or schizoaffective disorder',
    ],
    contraindications: [
      'History of clozapine-induced agranulocytosis',
      'Uncontrolled epilepsy',
      'Severe CNS depression',
      'Myeloproliferative disorders',
    ],
    sideEffects: [
      'Agranulocytosis (1-2% risk)',
      'Seizures (dose-dependent)',
      'Myocarditis (especially early treatment)',
      'Significant weight gain and metabolic effects',
      'Sedation',
      'Hypersalivation',
      'Constipation (can lead to ileus)',
      'Tachycardia',
      'Orthostatic hypotension',
      'Very low EPS risk',
    ],
    interactions: [
      'CYP1A2 substrate (smoking decreases levels)',
      'CYP3A4 substrate',
      'Avoid with other myelosuppressive agents',
    ],
    monitoring: [
      'Absolute neutrophil count (ANC): weekly x 6 months, biweekly x 6 months, then monthly',
      'REMS program enrollment required',
      'Weight, glucose, lipids',
      'Monitor for myocarditis symptoms (especially first month)',
      'Constipation management',
    ],
    dosing: {
      starting: '12.5 mg daily or BID, titrate slowly',
      therapeutic: '300-450 mg daily (range 150-900)',
      maximum: '900 mg daily',
    },
    switchingNotes: [
      'Reserved for treatment-resistant cases',
      'Requires REMS enrollment and regular ANC monitoring',
      'Switching from clozapine is challenging; often maintained lifelong',
    ],
    warnings: [
      'Black box: Severe neutropenia/agranulocytosis; orthostatic hypotension, bradycardia, syncope; seizures; myocarditis, cardiomyopathy; dementia-related psychosis mortality',
      'REMS program mandatory',
      'Only for treatment-resistant schizophrenia',
      'Most effective antipsychotic but highest risk profile',
    ],
    specialPopulations: {
      pregnancy: 'Category B (but risks remain).',
      lactation: 'Excreted in milk; avoid.',
      geriatric: 'Avoid in dementia; very high risk.',
      renal: 'Caution.',
      hepatic: 'Caution.',
    },
  },
];
